Logo-npj
Submitted: 16 Nov 2021
Accepted: 09 Apr 2022
ePublished: 24 Apr 2022
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

J Nephropharmacol. 2024;13(1): e10446.
doi: 10.34172/npj.2022.10446
  Abstract View: 8180
  PDF Download: 357

Original

Correlation of glomerular filtration rate and fibroblast growth factor-23 levels in chronic kidney disease; sub analysis chronic kidney disease–mineral and bone disorder study

Akiko Syawalidhany Tahir 1* ORCID logo, Haerani Rasyid 2 ORCID logo, Syakib Bakri 2 ORCID logo, Hasyim Kasim 2 ORCID logo, Tutik Harjianti 1 ORCID logo, Muhammad Luthfi Parewangi 1 ORCID logo, Harun Iskandar 1 ORCID logo, Arifin Seweng 3 ORCID logo

1 Department of Internal Medicine, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
2 Nephrology and Hypertension Division, Department of Internal Medicine, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
3 Department of Biostatistics, Faculty of Public Health, Hasanuddin University, Makassar, Indonesia
*Corresponding Author: Akiko Syawalidhany Tahir, Email: akikostahir@gmail.com, akikostahir@yahoo.com, , Email: tahiras17c@student.unhas.ac.id

Abstract

Introduction: One of the chronic kidney disease (CKD) manifestations is mineral disorder, such as phosphate and calcium. Phosphatonin levels are regulated by the hormone phosphatonin, which the most commonly associated with CKD is fibroblast growth factor-23 (FGF-23), mainly synthesized by bone cells. The increase in FGF-23 in CKD subjects is a physiological response to stabilize phosphate levels. Several conditions can increase FGF-23 levels including age, body mass index (BMI), diabetes mellitus (DM), and hypertension.

Objectives: This study aims to test the correlation between FGF-23 levels at various stages of glomerular filtration rate (GFR) in CKD.

Patients and Methods: This study is observational with a cross-sectional approach conducted at Wahidin Sudirohusodo and Unhas hospitals of Makassar. Subjects are CKD patients which meet inclusion criteria. Intact serum FGF-23 levels were measured using an ELISA (enzyme-linked immunosorbent assay) kit (Immutopics). Statistical analysis was conducted using ANOVA test, Mann-Whitney U, and Spearman’s correlation tests. Statistical results are considered significant if P<0.05.

Results: The research was conducted on 78 subjects with CKD stages 3, 4 and 5, which consisted of 40 men and 38 women. The correlation test showed that the lower the GFR, the higher the FGF-23 level (P<0.05). No significant correlation between age, body mass index, diabetes mellitus, and hypertension with FGF-23 were detected (P>0.05).

Conclusion: We found that every increase in the CKD stages and decrease of GFR, would be associated with an increase in the plasma levels of FGF-23. However, FGF-23 plasma concentration had no significant correlation with age, BMI, DM, and hypertension.


Implication for health policy/practice/research/medical education:

Increased FGF-23 level in chronic kidney disease patients is a physiological response to stabilize phosphate levels through increased urinary phosphate excretion. FGF-23 has the potential to be a novel, easily quantifiable biomarker for a strong prognostic predictor of mortality in chronic kidney disease. However, this measurement is still very limited and expensive; that becomes one of the weaknesses when conducted in daily practice.

Please cite this paper as: Tahir AS, Rasyid H, Bakri S, Kasim H, Harjianti T, Parewangi LM, Iskandar H, Seweng AD. Correlation of glomerular filtration rate and fibroblast growth factor-23 levels in chronic kidney disease; sub analysis chronic kidney disease– mineral and bone disorder study. J Nephropharmacol. 2024;13(1):e10446. DOI: 10.34172/npj.2022.10446

First Name
Last Name
Email Address
Comments
Security code


Abstract View: 8181

Your browser does not support the canvas element.


PDF Download: 357

Your browser does not support the canvas element.